TP53 and breast cancer: Our findings reveal, for the first time, that WT p53 downregulates GD3S expression, whereas p53 with specific GOF mutations upregulates GD3S expression, thereby promoting a GD2+ BC stem cell phenotype and providing a survival advantage to BC cells.